SUMMER is marked by a number of elite events, such as the Chelsea Flower Show, the Summer Exhibition at the Royal Academy and the Queen driving past in her carriage at Royal Ascot just after 2pm.
Indeed, the official programme included a few words from the Queen: "I am delighted to welcome you to Royal Ascot, one of the sporting events that I have been fortunate to enjoy throughout my life.
"Racing began at Ascot over 300 years ago and, while much has changed, the horses remain the stars, thrilling us with their beauty, brilliance and course.
"To everyone attending Royal Ascot this week, I hope you have a most enjoyable time.”
Bestway's guests at Royal Ascot certainly did. This year they had a good view of the royal family from an enclosed private area right next to the racecourse.
"Personally, I never bet," admitted Sir Anwar Pervez, founder chairman of Bestway who was perfectly dressed for the occasion in morning suit, waistcoat, dress shirt and tie. Once upon a time he even had a top hat.
The retail, cement, mining and pharma group entertained "863 guests" to a four-course luncheon last Friday (21) in the exclusive Pavilion Restaurant.
"This is our 27th Ascot," Sir Anwar told Eastern Eye: "People enjoy coming to Ascot - some guests came from Pakistan.”
This year Bestway Race Day at Royal Ascot raised funds for Save the Children.
Sir Anwar had warned in April when the group's annual results were filed at Companies House that "the uncertainty regarding Brexit will likely result in further austerity and continue to dampen economic growth".
But he also confirmed that the group had taken necessary measures to reduce key risks to the business.
The results showed the group's "overall revenues rose 9 per cent to £3.2 billion, despite profits falling on the back of some of its international businesses.”
Underlying profit before tax fell by 25 per cent to £331.9 million, it said, due to "difficult trading conditions in Pakistan and the devaluation of the Pakistani rupee" (in addition to its UK wholesale and retail operations, the group operates the largest cement factory and the second largest private bath in Pakistan).
On behalf of Sir Anwar and other directors, group chief executive Zameer Choudrey said recently that "in the UK £4.69m have been donated to local and national charities; £4.25m in scholarships to South Asian students and £2.61m to hospitals and schools. The UK's third largest pharmacist Well has donated more than £1.22m in support of local causes.”
He added: "In Pakistan, annually over 35,000 individuals are provided free medical treatment at our purpose-built health-care facilities and over 5,000 schoolchildren receive free education and meals at our dedicated local schools."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.